Unknown PHASE1 INTERVENTIONAL 4-arm NCT03183297

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001

A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of JMI-001 in Comparison With Fexofenadine and Naproxen Administered in Conjunction With Alcohol.

Sponsor: Sen-Jam Pharmaceutical

Conditions Veisalgia

Interventions Fexofenadine JMI-001 Naproxen placebo

Updated 6 times since 2017 Last updated: Jun 8, 2017 Started: Aug 31, 2017 Primary completion: Oct 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Veisalgia and is currently ongoing. Sen-Jam Pharmaceutical leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2021 — Oct 2021 [monthly]

Unknown Status PHASE1
Jul 2019 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jul 2017 — Jul 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sen-Jam Pharmaceutical

Data source: Sen-Jam Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.